Stocksigma LogoStocksigma Logo

Sakar Healthcare Reports Strong Q2FY27 Results Driven by Oncology Expansion

Sakar Healthcare posted robust Q2FY27 consolidated performance, with revenue rising 52% YoY to INR 8,741.61 lakhs and PAT surging 149% YoY to INR 1,130.69

Sakar Healthcare Reports Strong Q2FY27 Results Driven by Oncology Expansion

Sakar Healthcare Ltd 路 Investor Presentation 路 26 Oct 2026, 7:34 pm

Sakar Healthcare Reports Strong Q2FY27 Results Driven by Oncology Expansion Sakar Healthcare posted robust Q2FY27 consolidated performance, with revenue rising 52% YoY to INR 8,741.61 lakhs and PAT surging 149% YoY to INR 1,130.69 lakhs. EBITDA jumped 114% YoY to INR 2,434.53 lakhs, expanding margins by 800 bps to 28%. Growth is driven by its integrated, EU-GMP-approved Bavla oncology facility, executing 69 oncology contracts with commercial supplies underway across regulated markets. The company holds 22 granted global Marketing Authorisations, 33 active tech transfers, and targets over 100 overseas contracts within two years.

Original exchange filing (PDF)

More announcements from Sakar Healthcare Ltd

All Sakar Healthcare Ltd announcements